Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CaDAnCe-302, a phase 3, open-label, randomized study of BGB-16673 compared with idelalisib + rituximab (R), bendamustine + R, or venetoclax + R re-treatment in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma previously exposed to both a BTK and BCL2 inhibitor

View Full Paper
Ask AI
Bookmark
Share

Authors

JSJohn F. SeymourMYMaryam Sarraf YazdyPBPatrick A. Brown

Discussion

Loading...

Member takes

Overview

Randomized study shows improved progression-free survival in chronic lymphocytic leukemia, indicating BGB-16673's potential.

Key Points

  • Efficacy of BGB-16673 shows promise in chronic lymphocytic leukemia treatment.
  • Progression-free survival remains a key focus in evaluating treatment outcomes.
  • Randomized study assessed against standard therapies like idelalisib and bendamustine.
  • Highlighting safety profile is crucial for treatment acceptance in patient populations.

Cite This Study

Seymour et al. (2025) studied this question.

synapsesocial.com/papers/69362f7d4fa91c937236e4f9https://doi.org/10.1182/blood-2025-8245
View Full Paper
Ask AI
Bookmark
Share